AARP's new research finds price growth for top Part D prescription drugs has exceeded inflation, making a case for allowing ...

Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face ...

Drug pricing is influenced by numerous factors, but technology has the potential to strike the critical balance between ...

Beyond the influence of new therapies on drug pricing trends, Cowen’s report also accounted for the effects of legislation ...

Novo Nordisk expects Ozempic, which has been on the market since 2017, will be on Medicare's list of drugs to negotiate ...

Top Medicare Part D drugs without price negotiations have seen a 98% increase in list prices since their launch. Read more ...

Medicare recipients who take expensive prescriptions will get a break this year with a $2,000 cap on drug costs.

The Biden administration’s justification of the first cycle of Medicare drug price negotiations is fueling curiosity and ...

After failing to gain traction in previous years, legislation to establish a Prescription Drug Affordability Board (PDAB) is ...

Findings show the impact of drug companies’ relentless price increases, underscoring the importance of the changes included ...

New research from University of Iowa dispels the belief that pharmaceutical mergers lead to higher drug prices, showing a decrease in prices for generic drugs.

A key cost-saving provision of the Inflation Reduction Act (IRA) goes into effect in the new year, limiting annual ...